Cyclic azapeptides as integrin markers

Details Cyclic azapeptides as integrin markers Cyclic azapeptides as integrin markers

2008-07-25

2011-10-25

Jones, D L (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001690, C424S001730, C424S001810, C424S001850, C530S300000, C530S317000, C514S001000

Reexamination Certificate

active

08043601

ABSTRACT:
The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

REFERENCES:
patent: 6534478 (2003-03-01), Jonczyk et al.
patent: 6537520 (2003-03-01), Rajopadhye et al.
patent: 7666392 (2010-02-01), Kolb et al.
patent: 2003/0125243 (2003-07-01), Liu et al.
patent: WO 9901472 (1999-01-01), None
patent: WO2006135233 (2006-12-01), None
patent: WO2007018431 (2007-02-01), None
patent: WO 2008033557 (2008-03-01), None
patent: WO2008033561 (2008-03-01), None
Haubner et al (Bioconjugate Chemistry, 2004, vol. 15, pp. 61-69).
Chen et al (European Journal of Nuclear Medicine and Molecular Imaging, Aug. 2004, vol. 31, No. 8, pp. 1081-1089).
Cai Weibo et al; “A Thiol-Reactive F-Labeling Agent, N-[2-(4-18F-Fluorobenzamido) Ethyl]Maleimide, and Synthesis of RGD Peptide-Based Tracer for PET Imaging of alpha v beta 3 integrin Expression” Journal of Nuclear Medicine, Society of Nuclear Medicine, Reston, VA, US, vol. 47, No. 7, Jul. 1, 2006; pp. 1172-1180, XP002470156; Magazine; 2006; US.
Chen Xiaoyuan et al; ““Pegylated Arg-Gly-Asp Peptide: 64 Cu labeling and PET Imaging of Brain Tumor alphavbeta3-integrin expression”” Journal of Nuclear Medicine, Society of Nuclear Medicine, Reston, VA, US, vol. 45, No. 10, Oct. 1, 2004, pp. 1776-1783, XP002431122; Magazine; 2004; US.
Wu Yun et al; “MicroPET Imaging of glioma integrin (alpha)v(beta)3 expression using 64Cu-labeled tetrameric RGD peptide” Journal of Nuclear Medicine, Society of Nuclear Medicine, Reston, VA, US vol. 46, No. 10, Oct. 1, 2005; pp. 1707-1718, XP002470159; Magazine; 2005; US.
Goodman, et al. “Nanomolar Small Molecule Inhibitors for Alphavbeta6, Alphavbeta5, Integrins (XP-002204360” Published in Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 45, Jan. 31, 2002 (pp. 1045-1051); Magazine; Preliminary Report on Examination dated Nov. 25, 2009 in Application No. PCT/US2008/071266.
Haubner, et al., “(18F] Galacto-RGD: Synthesis, Radiolabeling, Metabolic Stability, and Radiation Dose Estimates” Bioconjugate Chemistry, ACS, Washington, DC, US, vol. 15, No. 1, Jan. 1, 2004, pp. 61-69.
Chen, et al., “MicroPET Imaging of brain tumor angiogenesis with 18 F labeled PEGylated RGD peptide”, European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag, Heidelberg, DE, vol. 31, No. 8, Aug. 1, 2004.
Belvisi et al., “Potent Integrin Antagonists From a Small Library of RGD-including Cyclic Pseudopeptides”, Organic Letters, vol. 3, No. 7, 2001, pp. 1001-1004.
Ryppa Claudia et al., “In vitro and in vivo evalution of doxorubicin conjugates with the divalent peptide E-[c(RGDfK) (2)] that targets integrin alpha(v)beta(3)” Bioconjugate Chemistry, vol. 19, No. 7, Jul. 2008, pp. 1414-1422.
Dijkgraaf Ingrid et al., “Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1, 3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes” Organic and Biomolecular Chemistry, Royal Society of Chemistry, Cambridge, GB, vol. 5, No. 6, Mar. 21, 2007; pp. 935-944.
Li Zi-Bo et al., “Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expressin” Bioconjugate Chemistry, ACS, Washington, DC, US; vol. 18, No. 6; Nov. 1, 2007, pp. 1987-1994.
Jeong Jae Min et al., “Preparation of a promising angiogenesis PET imaging agent: Ga-68-labeled c(RGDyK)-isothicoyanatobenzyl-1, 4, 7-triaza cyclononane-1, 4, 7-triacetic acid and feasibility studies in mice” Journal of Nuclear Medicine, vol. 49, No. 5, May 2008; pp. 830-836.
Hamidpour Mohsen et al., “The isolation and characterization of antiplatelet antibodies” European Journal of Haematology, vol. 76, No. 4, Apr. 2006; pp. 331-338.
International Search Report for Application No. PCT/US2009/002627 dated Nov. 17, 2009.
International Search Report for Application No. PCT/US2008/059599 dated Dec. 3, 2008.
Schmidt, et al., “Synthesis of Entantriomerically Pure and Compatibly Protected (2S, 3R)- and (2S, 3S)-Diaminobutyric Acids”, Synthesis, No. 12, 1992, pp. 1201-1202.
Kuijpers, et al., “Expedient synthesis of triazole-linked glycosyl amino acids and peptides”, Organic Letters, American Chemical Society, vol. 6, No. 18, Sep. 2, 2004, pp. 3123-3126.
Oppolzer, et al., “Non-destructive Cleavage of N-Acylsultams Under Neutral Conditions: Preparation of Enantriomerically Pure Fmoc-Protected alpha-Amino Acids”, Helvetica Chimica Acta, vol. 75, 1992, pp. 2572-2582.
Franke, et al., “Peptide Ligation through click chemistry for the generation of assembled and scaffolded peptides”, Tetrahedron Letters, Elsevier, Science Direct, vol. 46, No. 26, Jun. 27, 2005, pp. 4479-4482.
International Search Report in Application No. PCT/US2009/003309 dated Nov. 12, 2009.

Affiliated with

Also associated with

Rating

Cyclic azapeptides as integrin markers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic azapeptides as integrin markers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic azapeptides as integrin markers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4278875